- Email: [email protected]
Correction to Lancet Oncol 2014; 15: 966–74
Corrections
Correction to Lancet Oncol Correction to Lancet Oncol Correction to Lancet Oncol 2014; 15: 933, 941 2014; 15: 966–74 2012; 13: 1261, 1263 Sant M, Minicozzi P, Mournier M, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 2014; 15: 931–42—In table 1 of this Article, 176 (8·1%) patients were available for survival analysis for Hodgkin’s lymphoma in Sassari, Italy. Also, the declaration of interests should have been “MMa has received personal fees from Roche, outside the submitted work. The other authors declare no competing interests”. Finally, the contributors section should have stated that MS, PM, MMo, LAA, HB, BH, RM-G, AM, MMa, GO-G, OV, RDA, and the EUROCARE-5 Working Group revised the paper”. These corrections have been made to the online version as of Sept 1, 2014.
van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014; 15: 966–74— The supplementary appendix for this Article has been resupplied to include a table of treatment-emergent adverse events of grade 4 or higher. The first sentence of ninth paragraph of the Results section now reads “Grade 3 or higher events reported in more than 5% of siltuximab-treated patients were fatigue and night sweats and, in participants receiving placebo, anaemia (table 3); treatmentemergent adverse events of grade 4 or higher are shown in the appendix.” These changes have been made to the online version as of Sept 1, 2014.
Denham JW, Wilcox C, Joseph D, et al. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol 2012; 13: 1260–70—In this Article, the PSA strata for randomisation should read “(<10 μg/L, 10–20 μg/L, and >20 μg/L)”. Data for initial PSA groupings and radiation dose in table 1 were incorrect; the corrected table is shown below. These corrections have been made to the online version as of Sept 1 2014. STAS (n=268)
STAS+Z (n=268)
ITAS (n=268)
ITAS+Z (n=267)
69·1 (63·8–73·3)
68·6 (63·3–73·2)
68·2 (62·6–72·3)
170 (63%)
171 (64%)
170 (63%)
169 (63%)
98 (37%)
97 (36%)
98 (37%)
98 (37%)
Age (years; median, 69·3 IQR) (63·9–73·3) T stage T2 T3,4 Gleason score
Correction to Lancet Oncol 2014; 15: 957
<7
26 (10%)
25 (9%)
25 (9%)
25 (9%)
7
155 (58%)
155 (58%)
138 (51%)
151 (57%)
>7
87 (32%)
88 (33%)
105 (39%)
91 (34%)
Initial PSA group (μg/L)
Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncol 2014; 15: 954–65—In the section on most common adverse events in table 3 of this Article, the number of patients who had recently progressed on vemurafenib who had any grade photosensitivity or sunburn should read 10 (15%), and the number of patients who had never received a BRAF inhibitor with any grade photosensitivity or sunburn should read 42 (67%). These corrections have been made to the online version as of Sept 1, 2014.
<10 10–20 >20
74 (28%)
74 (28%)
72 (27%)
73 (27%)
110 (41%)
109 (41%)
110 (41%)
110 (41%)
84 (31%)
85 (32%)
86 (32%)
84 (32%)
Initial testosterone group (nmol/L)* <8
17 (6%)
12 (4%)
16 (6%)*
11 (4%)*
≥8
251 (94%)
256 (96%)
251 (94%)*
254 (95%)*
Initial haemoglobin group (g/L) <130
8 (3%)
15 (6%)
16 (6%)
11 (4%)
≥130
260 (97%)
253 (94%)
252 (94%)
256 (96%) 62 (23%)
Radiation dose HDRB
57 (21%)
57 (21%)
61 (23%)
66 Gy
30 (11%)
30 (11%)
32 (12%)
33 (12%)
70 Gy
111 (41%)
108 (40%)
106 (40%)
102 (38%)
74 Gy
68 (25%)
65 (24%)
64 (24%)
65 (24%)
2 (1%)
8 (3%)
5 (2%)
5 (2%)
Not given or not per protocol
Data are number (%) or median (IQR). STAS=short-term androgen suppression (leuprorelin) for 6 months with radiotherapy. STAS+Z=short-term androgen suppression (leuprorelin) for 6 months with radiotherapy plus zoledronic acid. ITAS=intermediateterm androgen suppression (leuprorelin) for a total of 18 months with radiotherapy. ITAS+Z=intermediate-term androgen suppression (leuprorelin) for a total of 18 months with radiotherapy plus zoledronic acid. PSA=prostate-specific antigen. HDRB=high-dose rate brachytherapy. *Three patients did not have an initial testosterone value.
Table 1: Characteristics of the 1071 randomly assigned patients and their tumours
www.thelancet.com/oncology Vol 15 September 2014
e417
Correction to Lancet Oncol Correction to Lancet Oncol Correction to Lancet Oncol 2014; 15: 933, 941 2014; 15: 966–74 2012; 13: 1261, 1263 Sant M, Minicozzi P, Mournier M, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 2014; 15: 931–42—In table 1 of this Article, 176 (8·1%) patients were available for survival analysis for Hodgkin’s lymphoma in Sassari, Italy. Also, the declaration of interests should have been “MMa has received personal fees from Roche, outside the submitted work. The other authors declare no competing interests”. Finally, the contributors section should have stated that MS, PM, MMo, LAA, HB, BH, RM-G, AM, MMa, GO-G, OV, RDA, and the EUROCARE-5 Working Group revised the paper”. These corrections have been made to the online version as of Sept 1, 2014.
van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014; 15: 966–74— The supplementary appendix for this Article has been resupplied to include a table of treatment-emergent adverse events of grade 4 or higher. The first sentence of ninth paragraph of the Results section now reads “Grade 3 or higher events reported in more than 5% of siltuximab-treated patients were fatigue and night sweats and, in participants receiving placebo, anaemia (table 3); treatmentemergent adverse events of grade 4 or higher are shown in the appendix.” These changes have been made to the online version as of Sept 1, 2014.
Denham JW, Wilcox C, Joseph D, et al. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol 2012; 13: 1260–70—In this Article, the PSA strata for randomisation should read “(<10 μg/L, 10–20 μg/L, and >20 μg/L)”. Data for initial PSA groupings and radiation dose in table 1 were incorrect; the corrected table is shown below. These corrections have been made to the online version as of Sept 1 2014. STAS (n=268)
STAS+Z (n=268)
ITAS (n=268)
ITAS+Z (n=267)
69·1 (63·8–73·3)
68·6 (63·3–73·2)
68·2 (62·6–72·3)
170 (63%)
171 (64%)
170 (63%)
169 (63%)
98 (37%)
97 (36%)
98 (37%)
98 (37%)
Age (years; median, 69·3 IQR) (63·9–73·3) T stage T2 T3,4 Gleason score
Correction to Lancet Oncol 2014; 15: 957
<7
26 (10%)
25 (9%)
25 (9%)
25 (9%)
7
155 (58%)
155 (58%)
138 (51%)
151 (57%)
>7
87 (32%)
88 (33%)
105 (39%)
91 (34%)
Initial PSA group (μg/L)
Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncol 2014; 15: 954–65—In the section on most common adverse events in table 3 of this Article, the number of patients who had recently progressed on vemurafenib who had any grade photosensitivity or sunburn should read 10 (15%), and the number of patients who had never received a BRAF inhibitor with any grade photosensitivity or sunburn should read 42 (67%). These corrections have been made to the online version as of Sept 1, 2014.
<10 10–20 >20
74 (28%)
74 (28%)
72 (27%)
73 (27%)
110 (41%)
109 (41%)
110 (41%)
110 (41%)
84 (31%)
85 (32%)
86 (32%)
84 (32%)
Initial testosterone group (nmol/L)* <8
17 (6%)
12 (4%)
16 (6%)*
11 (4%)*
≥8
251 (94%)
256 (96%)
251 (94%)*
254 (95%)*
Initial haemoglobin group (g/L) <130
8 (3%)
15 (6%)
16 (6%)
11 (4%)
≥130
260 (97%)
253 (94%)
252 (94%)
256 (96%) 62 (23%)
Radiation dose HDRB
57 (21%)
57 (21%)
61 (23%)
66 Gy
30 (11%)
30 (11%)
32 (12%)
33 (12%)
70 Gy
111 (41%)
108 (40%)
106 (40%)
102 (38%)
74 Gy
68 (25%)
65 (24%)
64 (24%)
65 (24%)
2 (1%)
8 (3%)
5 (2%)
5 (2%)
Not given or not per protocol
Data are number (%) or median (IQR). STAS=short-term androgen suppression (leuprorelin) for 6 months with radiotherapy. STAS+Z=short-term androgen suppression (leuprorelin) for 6 months with radiotherapy plus zoledronic acid. ITAS=intermediateterm androgen suppression (leuprorelin) for a total of 18 months with radiotherapy. ITAS+Z=intermediate-term androgen suppression (leuprorelin) for a total of 18 months with radiotherapy plus zoledronic acid. PSA=prostate-specific antigen. HDRB=high-dose rate brachytherapy. *Three patients did not have an initial testosterone value.
Table 1: Characteristics of the 1071 randomly assigned patients and their tumours
www.thelancet.com/oncology Vol 15 September 2014
e417